Hadassah

Hadassah and Kadimastem Co-Design Embryonic Stem Cell Protocol for ALS Clinical Trial

Monday, Jan 30 2017

Hadassah and Kadimastem co-design embryonic stem cell protocol.

Kadimastem, an Israeli biotechnology company, will be conducting a Phase I/IIA clinical trial with its stem cell product, AstroRx®, derived from Hadassah’s clinical grade human embryonic stem cell (hESC) lines.

The trial, whose protocol was designed with Hadassah, is scheduled to begin at the hospital toward the end of 2017, with the exact time frame depending on completion of the pre-clinical safety studies and necessary ethical approval.  

The trial will include 21 patients and be conducted by Hadassah’s Department of Neurology, under the direction of Prof. Tamir Ben-Hur. AstroRx® is a cell-based treatment based on astrocytes (nervous system tissue cells) produced from stem cells. According to Kadimastem,”its unique technology allows for large-scale production of the cells according to Good Manufacturing Practices (GMP) standards.” The astrocytes, Kadimastem reports, have the potential to be used as an off-the-shelf product for the treatment of large patient populations worldwide.

The administering of AstroRx® to the cohort will be performed by means of a standard injection directly into the spinal fluid, which is effective in dispersing the cells throughout the central nervous system. The injection of healthy, functioning astrocytes into the nervous system of ALS patients is expected to provide systemic support for the damaged motor neurons, thereby inhibiting disease progression and improving the patients' life expectancy and quality of life. The starting material from which the Company produced its product, is a line of unique human embryonic stem cells, developed in the laboratory of Prof. Benjamin Reubinoff, Director of Hadassah’s Human Embryonic Stem Cell Center, without the use of materials derived from animals. The cells were received under a licensing agreement with Hadasit, Hadassah’s technology transfer company.  Prof. Reubinoff and Prof. Ben-Hur are members of Kadima’s Scientific Advisory Board.

Prof. Michel Revel, the company's Chief Scientist, notes: "This is a very significant step in the development of Kadimastem's product for the treatment of ALS. We are happy about the collaboration with the distinguished Hadassah Medical Center and, in particular, with Prof. Tamir Ben Hur, head of the Neurology Department and Dr. Marc Gotkine, director of the ALS clinic."

Dr. Tamar Raz, Chief Executive Officer of Hadasit, adds: "We are proud that the starting material, which originated in Hadassah Hospital, has been developed and matured to a clinical trial product by Kadimastem, a company with which we have excellent cooperation. The ALS clinic in Hadassah in which the trial will be conducted is a global leader, and is experienced in recruiting patients for cell therapy."

 

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More